Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Zhen Ruan, Lisong Yang, Honghao Shi, Xiaomeng Yue, Yao Wang, Miaoying Liang & Hao Hu. (2021) The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 221-233.
Read now
Read now
Juan José Gorgojo-Martínez, Samuel J. P. Malkin, Virginia Martín, Nino Hallén & Barnaby Hunt. (2020) Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Journal of Medical Economics 23:2, pages 193-203.
Read now
Read now
Articles from other publishers (14)
Zhen Feng, Wai Kei Tong, Xinyue Zhang & Zhijia Tang. (2023) Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Frontiers in Pharmacology 14.
Crossref
Crossref
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard & Lars Holger Ehlers. (2023) A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus. PharmacoEconomics.
Crossref
Crossref
Hans Liebisch-Rey, Andrea-Marcela Suarez-Chacon, Yuli-V. Fuentes, Jhosep Blanco, Joshua Kock, Sharon Lechtig-Wassermann & Rosa Helena Bustos. (2023) The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults. F1000Research 12, pages 914.
Crossref
Crossref
Zhen Ruan, Carolina Oi Lam Ung, Yang Shen, Yawen Zhang, Weihao Wang, Jingyi Luo, Huimin Zou, Yan Xue, Yao Wang, Hao Hu & Lixin Guo. (2022) Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China. Diabetes Therapy 13:10, pages 1737-1753.
Crossref
Crossref
Sara Stafford, Peter G. Bech, Adam Fridhammar, Nino Miresashvili, Andreas Nilsson, Michael Willis & Aiden Liu. (2022) Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting. Applied Health Economics and Health Policy 20:4, pages 543-555.
Crossref
Crossref
Nikolaos Kotsopoulos, Mark P. Connolly, Michael Willis, Andreas Nilsson, Åsa Ericsson & James Baker‐Knight. (2022) The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs. Diabetes, Obesity and Metabolism 24:6, pages 1038-1046.
Crossref
Crossref
Chinmay Dwibedi, Emelia Mellergård, Amaru Cuba Gyllensten, Kristoffer Nilsson, Annika S. Axelsson, Malin Bäckman, Magnus Sahlgren, Stephen H. Friend, Sofie Persson, Stefan Franzén, Birgitta Abrahamsson, Katarina Steen Carlsson & Anders H. Rosengren. (2022) Effect of self-managed lifestyle treatment on glycemic control in patients with type 2 diabetes. npj Digital Medicine 5:1.
Crossref
Crossref
Björn Eliasson, Åsa Ericsson, Adam Fridhammar, Andreas Nilsson, Sofie Persson & Barrie Chubb. (2022) Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting. PharmacoEconomics - Open 6:3, pages 343-354.
Crossref
Crossref
Kamran Qureshy, Andreas Ross Kirk, Michael Lyng Wolden, Amir Abbas Mohseni Zonoozi & Aiden Liu. (2022) A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada. Cardiovascular Endocrinology & Metabolism 11:2.
Crossref
Crossref
Shanshan Hu, Shuowen Wang, Chendong Qi, Shengying Gu, Chenyang Shi, Lin Mao & Guorong Fan. (2022) Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China. Frontiers in Pharmacology 13.
Crossref
Crossref
Francesco Maranta, Lorenzo Cianfanelli, Carlo Gaspardone, Vincenzo Rizza, Rocco Grippo, Marco Ambrosetti & Domenico Cianflone. (2021) Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. International Journal of Cardiology 338, pages 248-257.
Crossref
Crossref
Santiago Tofé, Iñaki Argüelles, Elena Mena, Guillermo Serra, Mercedes Codina, Juan Ramón Urgelés, Honorato García & Vicente Pereg. (2021) An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain. Endocrine and Metabolic Science 2, pages 100082.
Crossref
Crossref
Virginia Martín, Josep Vidal, Samuel J. P. Malkin, Nino Hallén & Barnaby Hunt. (2020) Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Advances in Therapy 37:10, pages 4427-4445.
Crossref
Crossref
Michael Willis, Adam Fridhammar, Jens Gundgaard, Andreas Nilsson & Pierre Johansen. (2020) Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. PharmacoEconomics 38:9, pages 953-969.
Crossref
Crossref